Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon Reports Positive Phase 1 ANV600 Data at ASCO 2026

Anaveon presented new clinical data for its legacy oncology asset, ANV600 (sunekafusp alpha), from the EXPAND-1 Phase 1 study at the 2026 ASCO Annual Meeting. The data demonstrated encouraging preliminary antitumor activity and a promising safety-efficacy profile in patients with advanced solid tumors, including a complete response in a non-small cell lung cancer patient. As Anaveon strategically pivots to immunology, the company is actively seeking global development and commercialization partners for its oncology portfolio, which includes ANV600, a first-in-class PD-1-targeted IL-2R-βγ agonist.

• The EXPAND-1 Phase 1 study showed meaningful clinical benefit for ANV600, both as monotherapy and in combination with pembrolizumab. This included a complete response in a CPI-progressing NSCLC patient, partial responses in two patients, and disease control rates of 42% for monotherapy and 59% for combination therapy in advanced solid tumors.
• ANV600 was well-tolerated as monotherapy and in combination, demonstrating a promising safety-efficacy profile. The trial also provided compelling proof-of-mechanism, showing increased absolute counts of CD8+ T cells and NK cells over regulatory T cells, consistent with its design as a non-blocking PD-1-targeted IL-2R-βγ agonist.
• Anaveon is strategically shifting its focus to its core immunology pipeline. Consequently, the company is actively seeking global development and commercialization partners for its oncology portfolio, including ANV600 and other assets like ANV700 and ANV419, to maximize their potential in CPI-resistant NSCLC and other immuno-oncology indications.

Addressing Unmet Needs in Advanced Solid Tumors and CPI Resistance

Current treatment approaches for advanced solid tumors face significant limitations that have hindered meaningful progress in patient outcomes. Despite decades of research, the effectiveness of standard therapies remains constrained by fundamental challenges related to resistance mechanisms, toxicity profiles, and the complex biology of metastatic disease. These limitations underscore the urgent need for innovative therapeutic strategies that can overcome existing barriers.

• Limited efficacy and survival benefit: Traditional treatment modalities including radiotherapy, chemotherapy, and targeted agents are predominantly palliative, providing only modest improvements in survival with persistently low long-term survival rates for most patients with advanced cancer

• Treatment-related toxicity and resistance: The effectiveness of chemotherapy and radiation is significantly limited by treatment-related toxicity and the emergence of resistance mechanisms, with efficient DNA repair in cancer cells serving as an important mechanism for therapeutic resistance

• Inadequate focus on metastatic disease: Current treatments based on DNA damage-induced cell death neglect the fundamental features of cancer cell invasion and metastasis, which are responsible for 90% of human cancer deaths and represent the major reason for treatment failure

• Poor drug delivery and bioavailability: Conventional chemotherapy approaches face limitations imposed by solid tumor pathophysiology, resulting in nonspecific drug uptake by healthy cells, poor bioavailability, and systemic toxicity

• Insufficient treatment options for refractory patients: Patients unresponsive to standard or experimental therapies have limited alternatives, facing poor quality of life with no established strategies to reduce the risk of primary tumor recurrence or secondary cancers among survivors

• Challenges with novel immunotherapies: CAR-T cell therapy efficacy in solid tumors is impeded by limited tumor infiltration, compromised cancer recognition, decreased cytotoxicity, heightened T-cell exhaustion, absence of memory phenotypes, and inevitable toxicity concerns

Key Efficacy and Safety Findings from ANV600's EXPAND-1 Trial

Recent clinical trials in advanced solid tumors have demonstrated varying degrees of efficacy and safety across multiple novel therapeutic approaches. These studies encompass combination immunotherapies, targeted agents, and antibody-drug conjugates, providing important insights for treatment decision-making in heavily pretreated patient populations.

• NCT04337463 (Onatasertib + Toripalimab): This open-label phase 1/2 trial combined the mTORC1/2 inhibitor onatasertib (15-30mg daily) with PD-1 antibody toripalimab (240mg Q3W) in 46 patients, achieving an overall ORR of 26.1% and median PFS of 4.3 months, with particularly promising results in cervical cancer (ORR 52.4%, median PFS 5.8 months) and no dose-limiting toxicities observed

• Dabrafenib + Trametinib Meta-analysis: Following FDA accelerated approval in 2022 for BRAF V600-mutated metastatic solid tumors, this combination demonstrated consistent efficacy with median PFS of 4.5 months, median OS of 11.5 months, and cumulative ORR of approximately 30%, though grade 3-5 adverse events increased from 25% to 50% as off-label indications were studied

• Pembrolizumab + Lenvatinib in Ovarian Cancer: A retrospective study of 16 patients with recurrent MSS/pMMR ovarian cancer showed encouraging activity with 54% partial response rate among 13 evaluable patients, 6-month clinical benefit rate of 69%, and median PFS of 7.9 months, with three early discontinuations unrelated to drug toxicity

• Zilovertamab Vedotin (NCT04504916): This phase 2 study of the ROR1-targeting ADC in 102 patients with various advanced solid tumors demonstrated limited efficacy with ORR of only 1% at the higher dose schedule and 0% at the lower schedule, median PFS of 2.3 months, though treatment-related adverse events occurred in 83% of patients, most commonly fatigue and nausea

• Erdafitinib Meta-analysis: Analysis of 1,019 patients with FGFR1-4 mutated advanced solid tumors revealed differential efficacy by tumor type, with urothelial carcinoma patients showing superior median PFS and ORR compared to other solid tumors, while hyperphosphatemia remained the most prevalent adverse reaction across all tumor types (66.5-78.5%)

Anaveon's Targeted IL-2: Early Promise, Strategic Pivot, and Partnership Quest

The recent ASCO presentation of ANV600 (sunekafusp alpha) from Anaveon's EXPAND-1 Phase 1 study has brought a novel immuno-oncology asset into sharper focus. With encouraging preliminary antitumor activity, including a complete response in a non-small cell lung cancer patient, ANV600 demonstrates a promising safety-efficacy profile in advanced solid tumors. This bispecific antibody-cytokine fusion protein represents a sophisticated approach to cancer immunotherapy, designed to deliver IL-2Rβγ agonism specifically to PD-1+ cells by targeting a non-blocking epitope on PD-1. This innovative mechanism allows for the selective expansion of tumor antigen-specific CD8+ T cells, particularly progenitor exhausted (Tpex) and cytotoxic exhausted (Tcex) subsets, while crucially avoiding the systemic toxicity and regulatory T cell expansion often associated with conventional IL-2 therapies.

The strategic implications are significant. Anaveon's decision to pivot towards immunology means they are actively seeking global development and commercialization partners for their oncology portfolio, including ANV600. This presents a compelling opportunity for oncology-focused companies to acquire a potentially first-in-class asset that can act as both a monotherapy and a synergistic partner with existing PD-1 checkpoint inhibitors. Research shows ANV600's efficacy is dependent on CD8+ T cells and primarily driven by tumor-resident T cells, suggesting a targeted and potent effect within the tumor microenvironment.

However, potential partners and the broader market must consider several risks. The data, while promising, is from an early-stage Phase 1 study, meaning larger trials are needed to confirm these initial findings. The success of ANV600's future development is also heavily reliant on securing a suitable partnership, which introduces execution risk. Furthermore, the immuno-oncology landscape is highly competitive, and ANV600 will need to clearly demonstrate superior or differentiated benefits to carve out a significant market share. Despite these considerations, the unique mechanism and early clinical signal position ANV600 as a noteworthy candidate in the ongoing quest to enhance and refine T-cell mediated antitumor responses.